Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of the MTBVAC vaccine in adolescents and adults aged 12 to 55 years, both living with and without HIV in South Africa. This Phase 2a clinical trial aims to compare MTBVAC with the BCG vaccine in participants grouped based on their HIV status, CD4 T cell count, and interferon-gamma release assay IGRA status. The study is conducted by the HIV Vaccine Trials Network and involves randomized assignment without a placebo group. Participants will receive a single intradermal injection of either MTBVAC or BCG vaccine, each at a volume of 0.1 mL, administered in the upper arm at the start of the study. The study is divided into two parts and three cohorts, with enrollment proceeding sequentially based on safety criteria. Follow-up will continue for 48 weeks after vaccination to monitor safety and immune responses. During the study, participants will undergo various assessments including monitoring for adverse events up to 48 weeks, measurement of specific immune cell responses at baseline and multiple time points, gene expression profiling, and antibody levels. Researchers will also evaluate the acceptability of the vaccines. Safety monitoring includes tracking serious and solicited adverse events, with a focus on immune markers such as CD4 and CD8 T cells expressing certain cytokines. Participants will be asked to attend scheduled visits for these assessments throughout the study period.